Literature DB >> 3800349

Extravascular penetration of highly protein-bound flucloxacillin.

T Bergan, A Engeset, W Olszewski, N Ostby, R Solberg.   

Abstract

The pharmacokinetics of intravenously administered flucloxacillin (2.0 g to five volunteers) are described. The passage of flucloxacillin to peripheral lymph and suction skin blisters was monitored. This drug was selected because the high serum protein binding of 96% offered a particularly good opportunity for the study of the impact on tissue penetration. Flucloxacillin was assayed by high-pressure liquid chromatography, and pharmacokinetics were assayed by computerized curve fitting to accepted models. Penetration of flucloxacillin to extravascular foci was rapid. After 30 min the drug concentrations were 0.5 +/- 0.3 microgram/ml in lymph and 0.9 +/- 0.7 microgram/ml in blister fluid. The peak concentration was 11.7 +/- 5.6 micrograms/ml in lymph and 4.6 +/- 1.4 micrograms/ml in blister fluid. Concentrations in urine were above 111 +/- 50 micrograms/ml throughout the 8-h monitoring period, and urinary recovery was 60.4%. The half-life was 2.1 +/- 0.9 h in serum, 1.4 +/- 0.6 h in lymph, and 11.0 +/- 4.1 h in blister fluid. The differences in half-life were significant (P less than 0.05) between serum and blister fluid but not between lymph and serum. Penetration, as represented by the mean ratios of areas under the curve, was 19.7 +/- 8.1% to lymph and 38.2 +/- 11.7% to blister fluid. The flucloxacillin distribution volume during the phase of elimination was 36.4 +/- 16.0 liters and the total body clearance was 12.9 +/- 5.5 liters. Flucloxacillin showed good tissue penetration, considering its very high serum protein binding. High flucloxacillin levels in lymph and blister fluid were explained in part by drug affinity to extravascular albumin. The major impacts of high protein binding are (i) slightly slower passage into extravascular sites, (ii) slightly later peak concentration, and (iii) levels in extravascular fluid that are persistently below those in serum.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3800349      PMCID: PMC176522          DOI: 10.1128/AAC.30.5.729

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacokinetics of bacampicillin and bacmecillinam in plasma and peripheral lymph.

Authors:  T Bergan; A Engeset; W Olszewski; R Solberg
Journal:  Lymphology       Date:  1979-06       Impact factor: 1.286

2.  Theory and practical impact of binding of antimicrobials to serum proteins and tissue.

Authors:  W A Craig; B Suh
Journal:  Scand J Infect Dis Suppl       Date:  1978

Review 3.  Penicillins.

Authors:  T Bergan
Journal:  Antibiot Chemother (1971)       Date:  1978

4.  Studies on human peripheral lymph. I. Sampling method.

Authors:  A Engeset; B Hager; A Nesheim; A Kolbenstvedt
Journal:  Lymphology       Date:  1973-03       Impact factor: 1.286

5.  Distribution to human peripheral lymph of amoxycillin and of ampicillin from the oral prodrug bacampicillin.

Authors:  T Bergan; A Engeset; W Olszewski; J Sjövall
Journal:  J Antimicrob Chemother       Date:  1983-11       Impact factor: 5.790

Review 6.  Changing patterns of hospital infections: implications for therapy. Changing concepts and new applications of antibiotic pharmacokinetics.

Authors:  W A Craig; B Vogelman
Journal:  Am J Med       Date:  1984-07-31       Impact factor: 4.965

Review 7.  Pharmacokinetics of tissue penetration of antibiotics.

Authors:  T Bergan
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

8.  Penetration of erythromycin into human peripheral lymph.

Authors:  T Bergan; A Engeset; W Olszewski; K Josefsson; N Larsen
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

9.  Human leucocyte migration: studies with an improved skin chamber technique.

Authors:  K B Hellum; C O Solberg
Journal:  Acta Pathol Microbiol Scand C       Date:  1977-12
  9 in total
  12 in total

1.  Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.

Authors:  Dana Maglio; Renli Teng; Per T Thyrum; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

Authors:  S K Nath; G A Foster; L A Mandell; C Rotstein
Journal:  Can J Infect Dis       Date:  1995-01

Review 3.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics.

Authors:  S Tawara; S Matsumoto; T Kamimura; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  Concentrations of flucloxacillin in heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.

Authors:  U Frank; E Schmidt-Eisenlohr; V Schlosser; G Spillner; M Schindler; F D Daschner
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

6.  Application of mathematical model to experimental chemotherapy of fatal murine pneumonia.

Authors:  T Hishikawa; T Kusunoki; K Tsuchiya; Y Uzuka; T Sakamoto; T Nagatake; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

7.  In vivo effect of flucloxacillin in experimental endocarditis caused by mecC-positive staphylococcus aureus showing temperature-dependent susceptibility in vitro.

Authors:  Stefano Mancini; Frédéric Laurent; Tiago R Veloso; Marlyse Giddey; Jacques Vouillamoz; François Vandenesch; Philippe Moreillon; José M Entenza
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

8.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

9.  Inhibition of flucloxacillin tubular renal secretion by piperacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics and pharmacodynamics of tigecycline.

Authors:  April Barbour; Stephan Schmidt; Benjamin Ma; Lars Schiefelbein; Kenneth H Rand; Olaf Burkhardt; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.